- Home
- MESO vs LILA Comparison
MESO vs LILA Comparison
Compare MESO & LILA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- LILA
- Stock Information
- Founded
- MESO 2004
- LILA 2017
- Country
- MESO Australia
- LILA Bermuda
- Employees
- MESO N/A
- LILA N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- LILA Cable & Other Pay Television Services
- Sector
- MESO Health Care
- LILA Telecommunications
- Exchange
- MESO Nasdaq
- LILA Nasdaq
- Market Cap
- MESO 1.3B
- LILA 1.3B
- IPO Year
- MESO N/A
- LILA N/A
- Fundamental
- Price
- MESO $15.17
- LILA $6.99
- Analyst Decision
- MESO Buy
- LILA Sell
- Analyst Count
- MESO 4
- LILA 1
- Target Price
- MESO $18.00
- LILA $6.50
- AVG Volume (30 Days)
- MESO 314.4K
- LILA 415.6K
- Earning Date
- MESO 08-28-2025
- LILA 08-07-2025
- Dividend Yield
- MESO N/A
- LILA N/A
- EPS Growth
- MESO N/A
- LILA N/A
- EPS
- MESO N/A
- LILA N/A
- Revenue
- MESO $5,670,000.00
- LILA $4,441,000,000.00
- Revenue This Year
- MESO $177.23
- LILA $1.89
- Revenue Next Year
- MESO $314.04
- LILA $3.13
- P/E Ratio
- MESO N/A
- LILA N/A
- Revenue Growth
- MESO N/A
- LILA N/A
- 52 Week Low
- MESO $5.78
- LILA $4.26
- 52 Week High
- MESO $22.00
- LILA $10.79
- Technical
- Relative Strength Index (RSI)
- MESO 60.94
- LILA 68.07
- Support Level
- MESO $14.45
- LILA $6.59
- Resistance Level
- MESO $16.23
- LILA $7.11
- Average True Range (ATR)
- MESO 0.57
- LILA 0.29
- MACD
- MESO 0.10
- LILA 0.01
- Stochastic Oscillator
- MESO 63.12
- LILA 88.67
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.